JP5896612B2 - 細胞足場材 - Google Patents
細胞足場材 Download PDFInfo
- Publication number
- JP5896612B2 JP5896612B2 JP2011059899A JP2011059899A JP5896612B2 JP 5896612 B2 JP5896612 B2 JP 5896612B2 JP 2011059899 A JP2011059899 A JP 2011059899A JP 2011059899 A JP2011059899 A JP 2011059899A JP 5896612 B2 JP5896612 B2 JP 5896612B2
- Authority
- JP
- Japan
- Prior art keywords
- nonwoven fabric
- cell
- sample
- cell scaffold
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims description 15
- 210000004027 cell Anatomy 0.000 claims description 66
- 239000004745 nonwoven fabric Substances 0.000 claims description 52
- 239000000835 fiber Substances 0.000 claims description 46
- 239000011148 porous material Substances 0.000 claims description 16
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 15
- 239000004626 polylactic acid Substances 0.000 claims description 15
- 230000010478 bone regeneration Effects 0.000 claims description 12
- 210000000963 osteoblast Anatomy 0.000 claims description 10
- 229940117828 polylactic acid-polyglycolic acid copolymer Drugs 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- -1 polybutylene succinate Polymers 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 229920000249 biocompatible polymer Polymers 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000002738 Giemsa staining Methods 0.000 description 8
- 229920002554 vinyl polymer Polymers 0.000 description 8
- 239000007984 Tris EDTA buffer Substances 0.000 description 7
- 238000001523 electrospinning Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- XKVYZLLWKHGKMT-BEJOYRPXSA-N Gemin D Natural products O([C@@H]([C@@H](O)C=O)[C@@H]1[C@@H](O)COC(=O)c2c(c(O)c(O)c(O)c2)-c2c(O)c(O)c(O)cc2C(=O)O1)C(=O)c1cc(O)c(O)c(O)c1 XKVYZLLWKHGKMT-BEJOYRPXSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- 210000001909 alveolar process Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930192479 gemin Natural products 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920002961 polybutylene succinate Polymers 0.000 description 2
- 239000004631 polybutylene succinate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920002721 polycyanoacrylate Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Chemical group 0.000 description 2
- 239000004800 polyvinyl chloride Chemical group 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Chemical group 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000011560 gingival overgrowth Diseases 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Chemical group 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920003227 poly(N-vinyl carbazole) Chemical group 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Chemical group 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001485 poly(butyl acrylate) polymer Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000921 polyethylene adipate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Chemical group 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Description
項1.
不織布を含む細胞足場材であって、
該不織布の平均ポアサイズが6〜50μmであり、
該不織布を構成する繊維が生体適合性繊維であり、
該繊維の平均繊維径が0.1〜3μmである、
細胞足場材。
項2.
生体適合性繊維が、生体適合性ポリマーを含んでなる繊維である、項1に記載の細胞足場材。
項3.
生体適合性ポリマーが、ポリ乳酸、ポリグリコール酸、ポリ乳酸−ポリグリコール酸共重合体、ポリカプロラクトン、キチン、コラーゲン、ポリリジン、ポリアルギニン、ヒアルロン酸、セリシン、セルロース、デキストラン、及びプルランからなる群より選択される少なくとも1種である、項2に記載の細胞足場材。
項4.
生体適合性繊維がポリ乳酸からなる繊維である、項1〜3のいずれかに記載の細胞足場材。
項5.
骨芽細胞増殖用である、項1〜4のいずれかに記載の細胞足場材。
項6.
項1〜5のいずれかに記載の細胞足場材を含む骨再生用材料。
見かけ密度(g/cm3)={サンプル重量(g)/サンプル体積(cm3)}
<歯周組織再生、口腔外科領域>
骨縁下欠損、クラスII根分岐部病変、退縮型欠損、裂開型欠損における組織再生誘導法;顎堤の骨造成術、歯槽提増大術、インプラント周囲の骨造成術における骨再生誘導法;顎堤形成術;上顎洞底挙上術におけるサイナスリフト法;抜歯窩の保存におけるソケットプリザベーション法;鼻腔底挙上術;骨延長手術、骨壊死部分の掻爬後の骨充填、骨組織のがん病巣掻爬後の骨充填、外傷による骨折の治療のための骨充填における骨再建術;ブリッジ下の歯肉増大、歯肉退縮への根面被服、歯間乳頭再建、その他歯肉増大など審美目的での施術、等
<整形外科領域>
骨延長手術;骨壊死部分の掻爬後、骨組織のがん病巣掻爬後、外傷による骨折の治療、脊椎圧迫骨折、偽関節治療における骨再建術;骨延長手術:骨粗鬆症の治療における薬効成分のキャリアー材としての使用、等
<皮膚再生用途>
やけど、挫傷、褥瘡、切り傷等の治療、人工皮膚の製造など
<口腔粘膜再生用途>
口腔炎、口腔内の傷、白板症等の治療など
不織布の製造
ポリ乳酸(フナコシ、Poly (L−Lactic Acid) 重量平均分子量300,000)を、ヘキサフルオロイソプロピルアルコール(HFIP):ジクロロメタン(DM)=8:2の混合溶液に溶解し、表1に示す各ポリ乳酸溶液を10gずつ調製した。調製したポリ乳酸溶液をシリンジ(Henke SASS WOLF、5mL)に充填し、針(テルモ、ノンベベル針21G1.1/2)をシリンジに装着して、エレクトロスピニング装置にセットした。シリンジからターゲットとなるアースとの距離を10cmとし、印加電圧10kVにて、アースに向けポリ乳酸を噴霧し(噴霧量0.6μL/sec、噴霧時間3時間)、各不織布を作成した。表1の通り、ポリ乳酸溶液濃度を変えて各不織布(不織布A〜D)を作成した。
以下の手順により、上記4種の不織布(不織布A〜D)の厚み、見かけ密度、空隙率(%)、ポアサイズ及び各不織布を構成する繊維の繊維径を測定した。
<厚み、見かけ密度、空隙率>
各不織布をそれぞれ長方形に切断(約4cm2程度)し、測定サンプルとした。当該測定サンプルの重量を測定した。さらに当該測定サンプルの縦及び横の長さをノギスで測定した。また、当該測定サンプルの厚みを、当該サンプルの切断面の電子顕微鏡(株式会社日立ハイテクノロジー、S−3200N,S−3000N)画像から求めた。そして、縦、横、厚みの長さを乗じて体積(cm3)を求めた。なお、厚みは、20箇所の測定値の平均値を用いた。
各不織布を直径2.5cmにカットし、プロピレン,1,1,2,3,3,3酸化ヘキサフッ素(商品名「Galwick」)に浸した。そして、ポアサイズをcapillary flow porometer(Porous Materials Inc、CFP-1200-AEL)を用いてハーフドライ法(ASTM E1294−89)により測定した。
走査型電子顕微鏡(株式会社日立ハイテクノロジー、S−3400N)を用いて各不織布断面を撮影し、500倍の電顕撮影映像からImage J(ver.1.43u)(NIH開発の画像処理ソフトフェア)により繊維径を測定した。繊維50本の繊維径の平均値を、各不織布の平均繊維径とした。
<細胞培養>
各評価サンプル(上記不織布A〜D)を、48穴シャーレ(住友ベークライト(株)、SUMILON、MS−80480)の底面と同じ大きさにカットし、48穴シャーレの底に設置した。評価サンプルをペニシリンカップ(ステンレス管)で押さえ、10%FBS/MEM培地(抗生物質とグルタミン酸を加えた10%FBS/MEM培地、以下10%FBS/MEM培地)を500μL加え湿らせた。プレート遠心機にて5min遠心した(2500rpm、室温)。減圧脱気し、5min遠心(2500rpm、室温)した。さらに200μLの10%FBS/MEM培地を加え、37℃、5%CO2インキュベーター内で、1hr以上インキュベートした。培地を500μL吸い取り廃棄した。事前に培養したMG−63(由来:ヒト骨肉腫、ヒューマンサイエンス研究資源バンク、Lot.05262004)を1.6×105cells/mLとなるように10%FBS/MEM培地に懸濁し、100μLずつ各wellに播種した(1.6×104cells/well)。5時間放置した後、200μLの10%FBS/MEM培地を加え、培養を開始した。培養5時間後、3日後、8日後のサンプルを細胞増殖性評価に使用した。細胞浸潤性評価には、5時間後のサンプルを取り出したシャーレを用いた。
既定の日数培養した細胞が付着した各評価サンプルを取り出し、それぞれPBS(リン酸緩衝生理食塩水)の入ったシャーレに加えた。PBSを含んだ状態の重量を測定し、乾燥重量とPBSを含んだ状態の評価サンプル重量から吸水量(PBSを含んだ状態の評価サンプル重量から、評価サンプルの実験に供される前の乾燥重量(シャーレ底面と同じ大きさにカットした時点で測定)を減じた量)を求めた。
細胞の浸潤性の評価として、培養5時間後の不織布を取り出した後のシャーレに付着する細胞数をDNAの蛍光強度として定量した。具体的には、次のようにして行った。すなわち、不織布を取り出した後のシャーレを500μLのPBSにて洗浄した。50μLの0.25%EDTA−トリプシン液(0.25%トリプシン、1mM EDTA)を加え、細胞をシャーレより剥がした。得られた細胞にPBS150μLとTE緩衝液を500μLとを加え細胞回収液とした。2回凍結融解(−80℃で凍結させ、室温で融解させる操作を2回繰り返した)を行い、その後超音波処理を30分行って、細胞を破砕した。TE緩衝液中にDNAを溶出させた100μLの細胞溶解液(凍結融解及び超音波処理を行って得た細胞破砕液)を96穴蛍光測定用プレート(Nunc black microwell、cat.137101)に加え、5分間室温でインキュベートして測定サンプルとした。
Claims (3)
- 不織布を含む細胞足場材であって、
該不織布の平均ポアサイズが7.5〜10μmであり、
該不織布を構成する繊維がポリ乳酸及び/又はポリ乳酸−ポリグリコール酸共重合体からなる繊維であり、
該繊維の平均繊維径が1〜3μmである、
細胞足場材。 - 骨芽細胞増殖用である、請求項1に記載の細胞足場材。
- 請求項1又は2に記載の細胞足場材を含む骨再生用材料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011059899A JP5896612B2 (ja) | 2011-03-17 | 2011-03-17 | 細胞足場材 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011059899A JP5896612B2 (ja) | 2011-03-17 | 2011-03-17 | 細胞足場材 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012192105A JP2012192105A (ja) | 2012-10-11 |
JP5896612B2 true JP5896612B2 (ja) | 2016-03-30 |
Family
ID=47084603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011059899A Active JP5896612B2 (ja) | 2011-03-17 | 2011-03-17 | 細胞足場材 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5896612B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5939565B2 (ja) * | 2012-02-21 | 2016-06-22 | 学校法人同志社 | 組織再生基材 |
JP6006610B2 (ja) * | 2012-10-19 | 2016-10-12 | グンゼ株式会社 | 生体吸収性組織補強材 |
JP7423081B2 (ja) | 2021-09-27 | 2024-01-29 | 学校法人藤田学園 | 骨修復デバイス及び手術用キット |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9704749D0 (en) * | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
JP2005211477A (ja) * | 2004-01-30 | 2005-08-11 | Gunze Ltd | 再生医療用支持体 |
ES2787501T3 (es) * | 2005-12-02 | 2020-10-16 | Sunstar Suisse Sa | Material biocompatible que presenta un tejido de nano- o microfibras no tejidas producido por procedimiento de electrohilado |
KR20080107405A (ko) * | 2006-03-06 | 2008-12-10 | 데이진 가부시키가이샤 | 골격 재료 |
JP5038639B2 (ja) * | 2006-03-06 | 2012-10-03 | 帝人株式会社 | 培養人工骨 |
JP5436205B2 (ja) * | 2006-05-12 | 2014-03-05 | スミス アンド ネフュー ピーエルシー | 足場 |
GB0702847D0 (en) * | 2007-02-14 | 2007-03-28 | Smith & Nephew | Scaffold with increased pore size |
JP2009136652A (ja) * | 2007-11-16 | 2009-06-25 | Takiron Co Ltd | 骨欠損部への充填材料 |
-
2011
- 2011-03-17 JP JP2011059899A patent/JP5896612B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012192105A (ja) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5925185B2 (ja) | 骨補填材含有不織布 | |
Zhu et al. | Bone regeneration with micro/nano hybrid-structured biphasic calcium phosphate bioceramics at segmental bone defect and the induced immunoregulation of MSCs | |
US20210128792A1 (en) | Electrospun matrix and method | |
US8338402B2 (en) | Scaffold | |
Lee et al. | Development of artificial dermis using 3D electrospun silk fibroin nanofiber matrix | |
AU2007251370B2 (en) | Scaffold | |
Guan et al. | Promoted dermis healing from full-thickness skin defect by porous silk fibroin scaffolds (PSFSs) | |
Safi et al. | Preparing polycaprolactone scaffolds using electrospinning technique for construction of artificial periodontal ligament tissue | |
CN108261557B (zh) | 一种用于伤口愈合的纳米纤维膜及其制备方法和应用 | |
JP2016524967A (ja) | 組織再生のための微細組織を用いて機能化された三次元スキャフォールド | |
CN101564555B (zh) | 一种组织工程骨移植物及其构建方法 | |
JP5896612B2 (ja) | 細胞足場材 | |
Ma et al. | Preparation of PLCL/ECM nerve conduits by electrostatic spinning technique and evaluation in vitro and in vivo | |
CN112295021A (zh) | 一种具有改良拓扑结构的皮肤移植物 | |
Ring et al. | Analysis of neovascularization of PEGT/PBT-copolymer dermis substitutes in balb/c-mice | |
JP6230332B2 (ja) | 骨補填材含有不織布 | |
CN114099775A (zh) | 负载SDF-1α/CGRP的HAp-SF人工骨膜及其制备方法 | |
JP2007236450A (ja) | 培養人工骨 | |
Nashchekina et al. | Distribution of bone-marrow stromal cells in a 3D scaffold depending on the seeding method and the scaffold inside a surface modification | |
Modi et al. | Translational Studies of Nanofibers-Based Scaffold for Skin and Bone Tissue Regeneration | |
Chong | Improving 3D Scaffolds for Skin Tissue Engineering using Advanced Biotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5896612 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |